FAM134B (E8Y9R) Rabbit mAb #83414
- WB
- IP
- IF
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 70 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:200 |
| Immunofluorescence (Immunocytochemistry) | 1:200 - 1:800 |
Storage
Protocol
Specificity / Sensitivity
FAM134B (E8Y9R) Rabbit mAb recognizes endogenous levels of total FAM134B protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro327 of human FAM134B protein.
Background
FAM134B (family with sequence similarity 134, member B), also referred to as JK-1 and RETREG1, is a cis-Golgi endoplasmic reticulum (ER) transmembrane protein that plays a role in ER homeostasis and may contribute to several human diseases (1). FAM134B contains a conserved LC3 interacting domain (LIR) that facilitates binding to LC3 and GABARAP family members and targets impaired ER to the autophagosome for degradation by ER-phagy (2). Deletion of FAM134B leads to ER expansion and stress-induced apoptosis (2). Expression of FAM134B has been linked to a number of pathological conditions, including viral infection, cancer, and neuronal disorders (1). FAM134B can potentially inhibit viral infection, as demonstrated by studies of FAM134B knockouts that resulted in significantly higher rates of Ebola virus replication (3). Mutations in FAM134B that lead to an accumulation of mis-folded proteins have also been associated with neuronal sensory disorders (2,4,5). The expression and mutational state of FAM134B can also have varying effects on cancer. Oncogenic effects of FAM134B were described in esophageal squamous carcinoma; whereas, it appears to have tumor suppressor activity in colorectal cancer (6-8).
- Islam, F. et al. (2018) J Cell Physiol 233, 4479-89.
- Khaminets, A. et al. (2015) Nature 522, 354-8.
- Chiramel, A.I. et al. (2016) J Infect Dis 214, S319-25.
- Murphy, S.M. et al. (2012) J Neurol Neurosurg Psychiatry 83, 119-20.
- Kurth, I. et al. (2009) Nat Genet 41, 1179-81.
- Tang, W.K. et al. (2007) Int J Mol Med 19, 915-23.
- Islam, F. et al. (2018) Genes Chromosomes Cancer 57, 240-51.
- Islam, F. et al. (2017) Hum Genet 136, 321-37.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.